イリノイ州における血液がんの臨床試験
イリノイ州内の拠点で、血液がんに関する16件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- The University of Chicago ( Site 0020), Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- 他54件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- 他49件
被験者募集中観察研究
全年齢 · 全性別 · 2026/09/17更新 · NCT04242095Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Chicago, Zion
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- Loyola University Medical Center, Maywood
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer
- Tempus AI, Chicago
被験者募集中観察研究健康なボランティア歓迎
全年齢 · 全性別 · 2026/08/10更新 · NCT07756034Mosaic Trial for Stem Cell Transplant Recipients
- Northwestern University Feinberg School of Medicine, Chicago
被験者募集中
18歳以上 · 全性別 · 2026/08/03更新 · NCT06960993A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- 他3件
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
- Northwestern University, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/11更新 · NCT06401356Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
被験者募集中第1相
13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Northwestern Memorial Hospital, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT03328078A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- Loyola University Medical Center, Maywood
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- University of Chicago Comprehensive Cancer Center, Chicago
被験者募集中
18歳以上 · 全性別 · 2026/02/20更新 · NCT05745285Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
- Northwestern University - Feinberg School of Medicine, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/11更新 · NCT07036133MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
- MPN Research Foundation, Chicago
被験者募集中観察研究
18歳以上 · 全性別 · 2026/01/23更新 · NCT07362225Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。